Date: Aug. 8, 2020
Source: School of Medicine
As Berberine (BBR), an active ingredient in traditional Chinese medicine, attracts attention for its multiple functions, Prof. Fei Jia's team in JNU’s School of Medicine published a relevant research paper in Clinical Cancer Research (IF:10.107) on Aug. 1. The research shows that BBR targetedly degrades BCR-ABL and BCR-ABL with the T315I mutation via the autophagic lysosome pathway. It further reveals a new system of the drug resistance for chronic myeloid leukemia (CML).
 

The research paper was reviewed in the same journal by Prof. Shannon Elisabeth Elf of the University of Chicago. She pointed out that the significance of the results should not be underestimated; as a mechanism overcoming resistance to Tyrosine kinase inhibitors (TKI), the complete degradation of BCR-ABL oncoproteins induced by BBR has a broad prospect for further application, thus representing a promising alternative to TKI therapy for BCR-ABL positive CML and potential ALL.
Doctoral researchers Yin Zhao and Gu Chunming and master researcher Huang Guiping are co-first authors. Fei is sole corresponding author.
Original link:
https://clincancerres.aacrjournals.org/content/early/2020/02/25/1078-0432.CCR-19-2460